Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance

Annals of Oncology

Volumn 11, Issue 9, 2000, Pages 1097-1104

  Gonzalez, R ^a   Silva, J M ^a   Sanchez, A ^a   Dominguez, G ^a   Garcia, J M ^a   Qi Chen, X ^b   Stroun, M ^b   Provencio, M ^a   Espana P ^a   Anker, P ^b   Bonilla, F ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Circulating DNA; Plasma DNA alterations; Prognostic factor; SCLC; Tumor DNA alterations

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MICROSATELLITE DNA; PROTEIN P53; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 12; CHROMOSOME 5; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; X CHROMOSOME;

ADULT; AGED; BASE SEQUENCE; CARCINOMA, SMALL CELL; DNA PRIMERS; DNA, NEOPLASM; DNA, SATELLITE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033788509     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008305412635     Document Type: Article

References (50)

1. Lung cancer mortality among males of Catalonia and Spain compared with other European countries between 1975-1977 and 1987-1989
2. Significant changes in the distribution of histologic types of lung cancer
3. Changing patterns of lung cancer incidence by histological type
4. Small-cell lung cancer
5. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
6. p53 genetic abnormalities and myc activation in human lung carcinoma
7. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome
8. Molecular abnormalities in lung cancer
9. Microsatellite alterations as clonal markers for the detection of human cancer
10. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small-cell lung cancer
11. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9p, 6p, and 6q in primary human small-cell lung cancer
12. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small-cell lung carcinoma
13. Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small-cell lung cancer
14. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease
15. Free DNA in the serum of cancer patients and the effect of therapy
16. Neoplastic characteristics of the DNA found in the plasma of cancer patients
17. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients
18. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: Diagnostic utility and prognostic significance
19. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
20. Molecular detection of genetic alterations in serum of colorectal cancer patients
21. Detection of mutant K-ras DNA in plasma or serum of patients with colorecta cancer
22. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia
23. TP53 gene mutations in plasma DNA of cancer patients
24. Microsatellite alterations in plasma DNA of small cell lung cancer patients
25. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients
26. Microsatellite alterations in serum DNA of head and neck cancer patients
27. Microsatellite analysis of plasma DNA from patients with clear-cell renal carcinoma
28. Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations
29. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer
30. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small-cell lung cancer patients
31. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients
32. Aberrant DNA methylation of tha p16(INK4a) gene in plasma DNA of breast cancer patients
33. Circulating DNA K-ras mutation in pancreatic adenocarcinoma
34. Plasma DNA as a marker of cancerous cell death. Investigation in patients suffering from lung cancer and in nude mice bearing human tumour
35. Plasma DNA level as a tumor marker in primary lung cancer
36. Optimization of nonradiol sotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus
37. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction
38. Colorectal neoplasms detected colonoscopically in at-risk members of colorectal cancer families stratified by the demonstration of DNA microsatellite instability
39. Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: Relationship to clinicopathological features and genetic alterations
40. Prognostic significance of DNA replication errors in young patients with colorectal cancer
41. Microsatellite instability at multiple loci in gastric carcinoma: Clinicopathologic implications and prognosis
42. Sporadic gastric carcinomas with microsatellite instability display a particular clinicpathologic profile
43. Microsatellite instability in endometrial carcinomas: Frequent replication errors in tumors of early onset and/or of poorly differentiated type
44. Cancers of the papilla of vater: Mutator phenotype is associated with good prognosis
45. Reduces survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors
46. Loss of heterozygosity at 3p in non-small-cell lung cancer and is prognostic implication
47. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small-cell lung cancer
48. Loss of heterozygosity frequently affects chromosome 17q in non-small-cell lung cancer
49. Microsatellite instability in human cancer: A prognostic marker for chemotherapy?